BioSpace News Archive

Bristol Myers Squibb announced that the European Commission has granted Marketing Authorization for Breyanzi, a CD19-directed chimeric antigen receptor T cell immunotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B after two or more lines of systemic therapy.

ChemImage, a leader in molecular chemical imaging, announced the appointment of Adam Saltman, MD, PhD as its Chief Medical Officer.

TheraCell Inc., a leading allograft solution company, announced that it has been acquired by Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies.

Tevogen Bio announced the strategic expansion of its leadership team with two new executives to support the biotech’s rapid operational growth, manufacturing readiness, and the continued development and utilization of its next generation precision T cell platform technology.

Rising burden of chronic diseases across the globe and growing geriatric population are some key factors driving the global healthcare distribution market revenue growth.

The report further provides details about each segments and regions covered in the global Artificial Pancreas Device System (APDS) market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The report further provides details about each segments and regions covered in the global Joint Replacement market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

Fresenius Medical Care announced today the appointment of noted clinical researcher and nephrologist Nwamaka (Amaka) Eneanya, MD as Head of Strategy and Operations for the company’s Global Medical Office.

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, announced the acquisition of MAST® platform from Lonza.

Surge in the prevalence of chronic diseases such as obesity and type I & type II diabetes, in the last few years, has increased the demand for treatments that involve negative pressure wound therapy devices, which in turn has been highly beneficial for the market growth.